Skip to content


  • Correction
  • Open Access

Correction to: Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol

  • 1, 2, 3,
  • 4,
  • 3, 5,
  • 1, 2,
  • 2,
  • 1, 3, 6, 7,
  • 3, 8,
  • 2,
  • 3, 5,
  • 2,
  • 2, 4,
  • 9, 10,
  • 9, 10,
  • 11,
  • 11,
  • 12 and
  • 1, 2, 3, 13Email author
BMC Cancer201818:110

  • Received: 9 November 2017
  • Accepted: 9 November 2017
  • Published:

The original article was published in BMC Cancer 2017 17:549


After publication of the original article [1] the authors found that Table 2 had been formatted incorrectly, meaning that some rows in the Table did not display the correct information.

An updated version of Table 2 is included with this Correction.
Table 2

Used cognitive tests, questionnaires and biological tests

MoCA Montreal Cognitive Assessment, WAIS Wechsler Adult Intelligence Scale, VOSP Visual Object and Space Perception Battery, fNART French National Adult Reading Test, ISI Insomnia Severity Index, VAS Visual Analog Scale, ADL Activities of Daily Living, IADL Instrumental Activities of Daily Living, MNA Mini-Nutritional Assessment

aCognitive assessment will be performed by neuropsychologists

bFor group of interest patients: before the start of the treatment or within 15 days after the start of treatment by abiraterone acetate or enzalutamide

cHad to be ≤3 on the 0–10 pain VAS scale to meet with inclusion pain criteria

dGeriatric assessment will be performed by a study nurse specialized in geriatric

eAdherence evaluation will be performed only in group of interest patients

fAt each time: CBC, platelets, albumin, CRP, prealbumin, iron, ferritin, transferrin, creatinin, sodium, potassium, ALT, AST, GGT, ALP, total bilirubin, TSH, T4, testosterone. At inclusion only: cortisol (at 8 h AM, fasting)

g1 EDTA (5 ml), 1 dry tube with gel (5 ml) and 1 dry tube without gel (5 ml)

The original article has also been updated.



Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

INSERM, U1086 ANTICIPE, Normandie University, UNICAEN, 14076 Caen, France
Clinical Research Department, Centre François Baclesse, 14076 Caen, France
Cancer and Cognition Platform, Ligue Nationale Contre le Cancer, 14076 Caen, France
Medical Oncology Department, Centre François Baclesse, 14076 Caen, France
Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Normandie University, UNIROUEN, INSERM, DC2N, 76000 Rouen, France
UPO, Gustave Roussy, 94800 Villejuif, France
NeuroHIV Rehabilitation Unit, Bicêtre University Hospital, 94275 Le Kremlin Bicêtre, France
Normandie University, UNICAEN, EPHE Paris, INSERM, U1077, 14000 Caen, France
Medical Oncology Department, Centre Henri-Becquerel, 76000 Rouen, France
Digestive and Urology Oncology Unit, Rouen University Hospital, 76000 Rouen, France
Medical Oncology and Hematology Department, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France
Medical Oncology Department, Gustave Roussy, 94800 Villejuif, France
Medical Oncology Department, CHU de Caen, 14000 Caen, France


  1. Lange M, Laviec H, Castel H, Heutte N, Leconte A, Léger I, Giffard B, Capel A, Dubois M, Clarisse B, Coquan E, Di Fiore F, Gouérant S, Bartélémy P, Pierard L, Karim F, Joly F. Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol. BMC Cancer. 2017;17:549. ArticlePubMedPubMed CentralGoogle Scholar


© The Author(s). 2018